Venetoclax

Sarcoma

IGM Biosciences, Inc.Small moleculePhase 1Dormant

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE National Cancer Institute (NCI)	Phase 2	BB
Cyclophosphamide Essen Biotech	Phase 2	BB
Ifosfamide City of Hope Medical Center	Phase 3	BB
Inno-206 City of Hope Medical Center	Phase 3	BB
Carboplatin OHSU Knight Cancer Institute	Phase 2	BB

View all 50 →

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant

BBB

Indicative ·

72 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

BB

Indicative ·

70 / 100

myeloid neoplasmDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.